A Phase 3 Randomized, Double Blind, Placebo-Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee.

Trial Profile

A Phase 3 Randomized, Double Blind, Placebo-Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2012

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jul 2012 Results published in the Journal of Pain.
    • 13 Jul 2010 Final patient number included based on abstract presentation at EULAR 2010.
    • 19 Jun 2010 results presented at 11th Annual Congress of the European League Against Rheumatism (EULAR) 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top